This rare genetic condition causes fatty substances to build up in the brain and nervous system. This results in loss of nerve function that worsens over time.
Update Date: 24.09.2026
By Mayo Clinic Staff
Metachromatic leukodystrophy (MLD) is a rare condition that causes fatty substances to build up in the brain and nervous system. These fatty substances are lipids called sulfatides. In MLD, the body doesn't make enough of a special enzyme to break down these sulfatides. Without this enzyme, sulfatides build up in the myelin covering that protects the nerve cells, damaging it. The damage causes the brain, spinal cord and nerves to lose function over time.
MLD is the result of a change in the ARSA gene. Most often, the changed gene is passed down by parents who have no symptoms. The child gets two copies of the changed gene, one from each parent, and has the condition.
There are three forms of MLD based on the age when symptoms start: late infantile form, juvenile form and adult form.
There is no cure for MLD yet. Depending on the form and age of onset, early diagnosis and treatment may help manage some symptoms and slow worsening of the condition.
Symptoms of metachromatic leukodystrophy include:
Mental health symptoms include:
The three forms of MLD can begin with different symptoms and vary in how quickly they worsen over time:
Talk with your healthcare professional if you or your child has symptoms that concern you.
Metachromatic leukodystrophy is caused by a changed gene that is passed from parents to children in an autosomal recessive pattern. This means that both parents have the changed gene, but they don't usually show symptoms of the condition. The child gets two copies of the changed gene, one from each parent, and has the condition. Sometimes the gene change happens by chance.
The most common cause of MLD is a change in the ARSA gene. This results in not having enough of the enzyme arylsulfatase A (ARSA) that breaks down lipids called sulfatides. Sulfatides build up in the myelin covering around the nerves. The buildup is toxic, destroying the myelin that protects the nerves. Over time, the damage affects how well the brain, spinal cord and nerves work.
Rarely, MLD is caused by a change in the PSAP gene. This gene change results in not having enough of a protein that stimulates ARSA to begin breaking down sulfatides. This also results in a buildup of sulfatides in the myelin covering around the nerves.
Children are at risk of metachromatic leukodystrophy if both parents carry a gene change known to cause the condition.
MLD happens more often in people with certain ancestry. Those at higher risk include Habbani Jews in Israel and members of the Navajo Nation in the U.S.
To diagnose metachromatic leukodystrophy, a neurologist talks with you about symptoms and medical history. A neurologist is a doctor who specializes in the brain, spinal cord, nerves and muscles. A neurological exam checks how well different parts of the nervous system are working. The nervous system includes the brain, spinal cord and nerves. The nervous system sends signals that control muscles and other bodily functions.
Tests that help diagnose metachromatic leukodystrophy and how severe it is include:
There is no cure for metachromatic leukodystrophy yet. Early treatment can help manage symptoms, prevent nerve damage, and stop or slow worsening of the condition. Early treatment also can help prevent complications and provide supportive care. Finding the condition early and getting early treatment may improve outcomes for some people with the condition.
Your healthcare team can work with you to help manage your symptoms over time. The goal is to improve quality of life.
MLD treatment can include:
Gene therapy. The U.S. Food and Drug Administration approved a gene therapy for MLD called atidarsagene autotemcel (Lenmeldy). The healthcare team collects a person's own bone marrow stem cells and uses them to create the therapy. The goal is to replace the changed genes that caused MLD with healthy genes. This can stop the condition from getting worse or slow it down.
The medicine is used for the late infantile form of MLD before symptoms begin. It also is used for the early juvenile form before symptoms begin or with early symptoms. Only one dose given by IV is needed, but it's expensive.
Supportive care can include:
Care for MLD can be complex and change over time. Regular checkups with a team of medical professionals experienced in managing this condition may help prevent some complications. Talk with your healthcare professional about finding support at home, school or work.
Clinical trials hold promise for more treatment options beyond gene therapy currently available for the early-onset forms of MLD. Potential treatments being studied include:
Talk to your healthcare professional about the possibility of participating in a clinical trial.
Caring for someone with metachromatic leukodystrophy can be challenging. More daily physical care may be needed as the condition worsens. You may not know what to expect, and you may worry about your ability to give the care needed.
To prepare yourself:
Make an appointment with your healthcare professional if you see symptoms that concern you. You may be referred to a doctor called a neurologist who specializes in evaluating and treating metachromatic leukodystrophy.
Here's some information to help you get ready for your appointment and what to expect from your healthcare professional.
Before your appointment make a list of:
Basic questions to ask may include:
Feel free to ask other questions during your appointment.
Your healthcare professional may ask:
Be ready to answer questions so that you have time to talk about what's most important to you.
© 2026 Mayo Foundation for Medical Education and Research. All rights reserved. Terms of Use